Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches

References

• Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M.-H., Vogel, Z., … Mechoulam, R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353, 23–31. doi:10.1016/S0014-2999(98)00392-6
   PubMed Web of Science ®Google Scholar
• Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA - Journal of the American Medical Association, 318, 1708–1709. doi:10.1001/jama.2017.11909
   PubMed Web of Science ®Google Scholar
• Carlini, E. A., Karniol, I. G., Renault, P. F., & Schuster, C. R. (1974). Effects of marihuana in laboratory animals and in man. British Journal of Pharmacology, 50, 299–309.
   PubMed Web of Science ®Google Scholar
• Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., … Cilio, M. R. (2016). Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. The Lancet Neurology, 15, 270–278. doi:10.1016/S1474-4422(15)00379-8
   PubMed Web of Science ®Google Scholar
• Doyle, E., & Spence, A. A. (1995). Cannabis as a medicine? British Journal of Anesthesia, 74, 726–361.
   Web of Science ®Google Scholar
• ElSohly, M. A., & Gul, W. (2014) Costituents of cannabis sativa, In Pertwee RG (Ed.), Handbook of cannabis (pp. 3–22). New York, NY: Oxford University Press.
   Google Scholar
• ElSohly, M. A., & Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sciences, 78, 539–548.
   PubMed Web of Science ®Google Scholar
• Fattore, L., & Fratta, W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 5, 1–12.
   PubMed Web of Science ®Google Scholar
• Fowler, C. J. (2003). Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. Brain Research. Brain Research Reviews, 41, 26–43.
   PubMedGoogle Scholar
• Haney, M., Gunderson, E. W., Rabkin, J., Hart, C. L., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2007). Dronabinol and marijuana in HIV-positive marijuana smokers: Caloric intake, mood, and sleep. Journal of Acquired Immune Deficiency Syndromes, 45, 545–554. doi:10.1097/QAI.0b013e31811ed205
   PubMed Web of Science ®Google Scholar
• Hazekamp, A., Ware, M. A., Muller-Vahl, K. R., Abrams, D., & Grotenhermen, F. (2013). The medicinal use of cannabis and cannabinoids—An international cross-sectional survey on administration forms. Journal of Psychoactive Drugs, 45, 199–210. doi:10.1080/02791072.2013.805976
   PubMed Web of Science ®Google Scholar
• Mechoulam, R., & Gaoni, Y. (1967). The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Letters, 8, 1109–1111.
   Google Scholar
• Mechoulam, R., & Hanus, L. (2000). A historical overview of chemical research on cannabinoids. Chemistry and Physics of Lipids, 108, 1–13.
   PubMed Web of Science ®Google Scholar
• Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology, 153, 199–215.
   PubMed Web of Science ®Google Scholar
• Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., … Ross, R. A. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacological Reviews, 62, 588–631.
   PubMed Web of Science ®Google Scholar
• Radwan, M. M., Wanas, A. S., Chandra, S., & ElSohly, M. A. (2017) Natural Cannabinoids of Cannabis and Methods of Analysis, In Suman Chandra, Hemant Lata, & Mahmoud A. ElSohly (Eds.), Cannabis Sativa L.: Botany and Biotechnology (pp. 161–182). Cham, Switzerland: Springer Publication.
   Google Scholar
• Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163, 1344–1364. doi:10.1111/j.1476-5381.2011.01238.x
   PubMed Web of Science ®Google Scholar
• Russo, E. B., & McPartland, J. M. (2003). Cannabis is more than simply Δ9-tetrahydrocannabinol. Psychopharmacology, 165, 431–432. doi:10.1007/s00213-002-1348-z
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramos, J. (2015). The entourage effect of the phytocannabinoids. Annals of Neurology, 77, 1083.
   PubMed Web of Science ®Google Scholar
• Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., … Cerny, T. (2006). Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannab. Journal of Clinical Oncology, 24, 3394–3400. doi:10.1200/JCO.2005.05.1847
   PubMed Web of Science ®Google Scholar
• Turner, C. E., ElSohly, M. A., & Boeren, E. G. (1980). Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod, 43, 169–234.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration (FDA). (March 2, 2018) Search for FDA Guidance Documents - Early Development Considerations for Innovative Combination Products. Retrieved from https://www.fda.gov/RegulatoryInformation/Guidances/ucm126050.htm
   Google Scholar
• Vandrey, R., Dunn, K. E., Fry, J. A., & Girling, E. R. (2012). A survey study to characterize use of Spice products (synthetic cannabinoids). Drug and Alcohol Dependence, 120, 238–241.
   PubMed Web of Science ®Google Scholar
• Vandrey, R., Raber, J. C., Raber, M. E., Douglass, B., Miller, C., & Bonn-Miller, M. O. (2015). Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA, 313, 2491. doi:10.1001/jama.2015.6613
   PubMed Web of Science ®Google Scholar
• Wachtel, S., ElSohly, M., Ross, S., Ambre, J., & De Wit, H. (2002). Comparison of the subjective effects of Delta9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology, 161, 331–339. doi:10.1007/s00213-002-1033-2
   PubMed Web of Science ®Google Scholar
• Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … Kleijnen, J. (2015). Cannabinoids for medical use. JAMA, 313, 2456. doi:10.1001/jama.2015.6358
   PubMed Web of Science ®Google Scholar
• Wilcox, M., Jacyno, M., Marcu, J., & Neal-Kababick, J. (2016). Improving quality control methods for cannabis-infused products using automated flash chromatography. Planta Medica, 82, PA32. doi:10.1055/s-0036-1578647
   Google Scholar
• Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., UK MS Research Group. (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. The Lancet, 362, 1517–1526. doi:10.1016/S0140-6736(03)14738-1
   PubMed Web of Science ®Google Scholar
• Zuardi, A. W. (2006). History of Cannabis as a medicine: A review. Rev Bras Psiquiatr, 28, 153–157.
   PubMed Web of Science ®Google Scholar